mTOR kinase inhibitors as a treatment strategy in hematological malignancies
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
mTOR kinase inhibitors as a treatment strategy in hematological malignancies
Authors
Keywords
-
Journal
Future Medicinal Chemistry
Volume 4, Issue 4, Pages 487-504
Publisher
Future Science, LTD
Online
2012-03-15
DOI
10.4155/fmc.12.14
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1
- (2011) Paige Yellen et al. CELL CYCLE
- Phospholipase D Mediates Nutrient Input to Mammalian Target of Rapamycin Complex 1 (mTORC1)
- (2011) Limei Xu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor
- (2010) B. Hoang et al. BLOOD
- Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia
- (2010) I. M. Ghobrial et al. CLINICAL CANCER RESEARCH
- The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia
- (2010) P. Saunders et al. HAEMATOLOGICA
- Rapamycin Inhibits Cytoskeleton Reorganization and Cell Motility by Suppressing RhoA Expression and Activity
- (2010) Lei Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis
- (2010) Ling Gu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
- (2010) Matthew R Janes et al. NATURE MEDICINE
- mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
- (2010) R. J. O. Dowling et al. SCIENCE
- Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine
- (2009) Agnieszka Janus et al. ANTI-CANCER DRUGS
- Rapamycin inhibits mTORC1, but not completely
- (2009) Carson C. Thoreen et al. Autophagy
- The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways
- (2009) M. Rahmani et al. BLOOD
- Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies
- (2009) David T. Teachey et al. BRITISH JOURNAL OF HAEMATOLOGY
- Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML
- (2009) Alexandra Boehm et al. European Journal of Internal Medicine
- Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
- (2009) S. Park et al. HAEMATOLOGICA
- mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein
- (2009) Manuela Mancini et al. LEUKEMIA RESEARCH
- Perifosine: Update on a novel Akt inhibitor
- (2009) Joell J. Gills et al. Current Oncology Reports
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL
- (2008) Thomas Decker et al. ANNALS OF HEMATOLOGY
- Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
- (2008) J. Bellmunt et al. ANNALS OF ONCOLOGY
- mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)
- (2008) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia
- (2008) D. T. Teachey et al. BLOOD
- Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells
- (2008) P. L. Tazzari et al. CANCER RESEARCH
- A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies
- (2008) D. A. Rizzieri et al. CLINICAL CANCER RESEARCH
- Anticancer Alkylphospholipids: Mechanisms of Action, Cellular Sensitivity and Resistance, and Clinical Prospects
- (2008) Wim van Blitterswijk et al. CURRENT PHARMACEUTICAL DESIGN
- The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma
- (2008) Philipp Baumann et al. EXPERIMENTAL CELL RESEARCH
- Deforolimus (AP23573) a novel mTOR inhibitor in clinical development
- (2008) Monica Mita et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells
- (2008) Michael G. Kharas et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies
- (2008) Monica M. Mita et al. JOURNAL OF CLINICAL ONCOLOGY
- The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism
- (2008) F Chiarini et al. LEUKEMIA
- PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
- (2008) S Park et al. LEUKEMIA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now